Effect of the St. John’s Wort Constituent Hyperforin on Docetaxel Metabolism by Human Hepatocyte Cultures

Bernard J. Komoroski,1 Robert A. Parise,2 Merrill J. Egorin,2,3,4 Stephen C. Strom,5 and Raman Venkataramanan1,2,5

Abstract

Background and Purpose: St. John’s wort is a commonly used herbal medication that increases cytochrome P450 3A (CYP3A) activity. Because docetaxel is inactivated by CYP3A, we studied the effects of the St. John’s wort constituent hyperforin on docetaxel metabolism in a human hepatocyte model.

Experimental Design: Hepatocytes, isolated from three donor livers, were exposed to hyperforin (0.1, 0.5, or 1.5 μmol/L) or rifampin (10 μmol/L) for 48 hours. After 48 hours, hyperforin- or rifampin-containing medium was replaced with medium containing 100 μmol/L docetaxel. After 1 hour, docetaxel metabolism was characterized by liquid chromatography-tandem mass spectrometry. Subsequent incubations characterized the specific cytochrome P450s that produced the docetaxel metabolites observed in hepatocyte incubations.

Results: Rifampin induced docetaxel metabolism 6.8- to 32-fold above docetaxel metabolism in control cultures. Hyperforin induced docetaxel metabolism in all three hepatocyte preparations. Hyperforin induction was dose-dependent and, at maximum, was 2.6- to 7-fold greater than that in controls. Docetaxel metabolites identified in rifampin- and hyperforin-treated hepatocyte preparations included the previously described tert-butyI – hydroxylated metabolite and two previously unidentified metabolites involving hydroxylation on the baccatin ring. CYP3A4 produced the tert-butyI – hydroxylated metabolite and the two ring-hydroxylated metabolites. CYP2C8 produced one of the newly described ring-hydroxylated metabolites.

Conclusions: Exposure to the St. John’s wort constituent hyperforin induces docetaxel metabolism in vitro. This implies that subtherapeutic docetaxel concentrations may result when docetaxel is administered to patients using St. John’s wort on a chronic basis. The results also show induction of previously undescribed metabolic pathways for docetaxel, one of which may be analogous to the known 6-α-hydroxylation of paclitaxel by CYP2C8.

In 2002, sales of botanical supplements in the United States reached nearly $293 million. St. John’s wort accounted for $15 million in sales, making it the seventh highest grossing botanical supplement (1). Several clinical studies have claimed St. John’s wort to be as effective as conventional therapy in the treatment of mild-to-moderate, but not severe, depression (2–6).

Several recent reports have documented decreased blood and plasma concentrations of cytochrome P450 3A4 (CYP3A4) substrates, such as indinavir, cyclosporine A, and imatinib, in patients concomitantly taking St. John’s wort (8–11). Similar observations have been documented for digoxin, a substrate of the intestinal transporter P-glycoprotein. Additional in vivo evidence has shown that St. John’s wort increased CYP3A and P-glycoprotein levels in rats (12). In primary human hepatocyte cultures, hyperforin, but not hypericin, was shown to induce CYP3A and CYP2C9 expression and activity with no effect on other common drug-metabolizing enzymes (13). Other investigators have suggested that chronic use of St. John’s wort can also induce CYP1A2 and CYP2C19 in vitro (14) and CYP1A2 in vivo in females (15).

Both CYP3A4 and P-glycoprotein are transcriptionally regulated by the nuclear orphan receptor pregnane X receptor.

Marketed St. John’s wort, an extract of the flowering portion of the plant Hypericum perforatum L., is a mixture of a number of biologically active, complex compounds. At 0.3 mg per capsule, the naphthodianthrone hypericin is used as a means of standardizing the marketed product. The phloroglucinol hyperforin, the most plentiful lipophilic compound in the extract, is a potent inhibitor of serotonin, norepinephrine, and dopamine reuptake (7).

The cost of publication of this article was defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Merrill J. Egorin, Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Room G27E, Hillman Research Pavilion, 5117 Centre Avenue, Pittsburgh, PA 15213-1863. Phone: 412-623-3252; Fax: 412-623-1212; E-mail: egorinmj@msx.upmc.edu.

© 2005 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-04-2488
Docetaxel is a taxane antineoplastic agent with a broad spectrum of antitumor activity (23–25) and a mechanism of action that involves abnormal polymerization of tubulin with resultant mitotic arrest (26, 27). Unlike paclitaxel, which is metabolized primarily by CYP2C8 (28–32), docetaxel is metabolized primarily by CYP3A4 (32, 33). Moreover, clinical studies have shown a correlation between docetaxel clearance and the dose-limiting neutropenia resulting from its use (34, 35). Specifically, patients with impaired hepatic function and decreased CYP3A4 activity experience greater myelosuppression than do patients with normal hepatic function and CYP3A4 activity (34, 35). To date, studies examining the effect of induction of CYP3A4 activity on docetaxel metabolism and its clinical pharmacodynamic effects have not been reported. As an initial approach to this question, we used primary human hepatocyte cultures to characterize the effect of hyperforin on docetaxel metabolism.

Materials and Methods

Chemicals and reagents. Williams’ E culture medium and the medium supplements, dexamethasone and insulin, were obtained from BioWhittaker (Walkersville, MD). Penicillin G/streptomycin was obtained from Cambrex (Walkersville, MD). Rifampin and NADPH were obtained from Sigma-Aldrich (St. Louis, MO). Amphotericin B was obtained from GENTEST (BD Biosciences, Woburn, MA). All solvents and other chemicals used were of high-performance liquid chromatography grade or the highest purity available.

Hepatocyte incubations. Hepatocytes were isolated from three donor liver tissues at the National Center for Toxicological Research (Jefferson, AR) on April 15, 2017. © 2005 American Association for Cancer Research. Donor information for human hepatocyte preparations

<table>
<thead>
<tr>
<th>Donor</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Race</th>
<th>Cause of death</th>
<th>Drug history</th>
<th>Viability (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HH1117</td>
<td>68</td>
<td>F</td>
<td>Caucasian</td>
<td>Cerebral vascular accident</td>
<td>Labetalol, verapamil, clonidine, metoclopramide, simvastatin, clopidogrel</td>
<td>82</td>
</tr>
<tr>
<td>HH1121</td>
<td>65</td>
<td>F</td>
<td>Caucasian</td>
<td>Cerebral vascular accident</td>
<td>No medications reported</td>
<td>78</td>
</tr>
<tr>
<td>HH1122</td>
<td>46</td>
<td>F</td>
<td>Caucasian</td>
<td>Head trauma</td>
<td>Triamterene, propranolol, levothryoxine, verapamil, alprazolam, modafinil, glatiramer acetate</td>
<td>76</td>
</tr>
</tbody>
</table>
and a mobile phase of acetonitrile/water/formic acid (37:63:0.1, v/v/v) that was pumped at 0.2 mL/min.

The mass spectrometer was a Micromass Quattro-micro bench-top, triple-stage mass spectrometer (Waters Corporation). The mass spectrometer operated under the following parameters: capillary voltage, 4.0 kV; cone voltage, 25.0 V; source and desolvation temperatures, 120°C and 400°C, respectively. The cone and desolvation gas flows were 110 and 550 L/h, respectively. Both the low mass and high mass resolution on quadrupole 1 and quadrupole 2 were set at 12. The collision cell was set at 35 V. The system was operated in electrospray ionization–positive mode with multiple reaction monitoring detection. The precursor > product ions monitored were the following: m/z 846 > 320 and m/z 846 > 549 (tert-butyl−hydroxylated metabolite); m/z 846 > 248 and m/z 830 > 248; m/z 830 > 549.5 (docetaxel); and m/z 876 > 308 and m/z 876 > 591 (paclitaxel internal standard). The internal standard ratio for each sample was calculated as the ratio of the total ion current of the two product ions monitored for docetaxel or metabolites divided by the total ion current of the two product ions monitored for paclitaxel. Standard curves of docetaxel were constructed by plotting the internal standard ratio versus the known concentration of docetaxel in prepared standards. Duplicate standard curves containing docetaxel concentrations of 1, 3, 10, 30, 100, 300, and 1,000 nmol/L were included with each analytic run. Standard curves were fit by linear regression with weighting by 1 / y², followed by back-calculation of concentrations. The system used Mass Lynx software version 4.0 (Waters Corporation) for operation and data acquisition.

Under the LC/MS/MS conditions described for hepatocyte incubations, docetaxel eluted at 10.7 minutes (Fig. 1A), and paclitaxel internal standard eluted at 13 minutes (Fig. 1B). The assay had a

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>Inducer</th>
<th>Hepatocyte preparation</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HH 1117</td>
<td>HH 1121</td>
</tr>
<tr>
<td>Tert-butyl−hydroxylated</td>
<td>DMSO (0.1%)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>Rifampin (10 μmol/L)</td>
<td>6.81</td>
<td>17.50</td>
</tr>
<tr>
<td></td>
<td>Hyperforin (0.1 μmol/L)</td>
<td>1.33</td>
<td>2.25</td>
</tr>
<tr>
<td></td>
<td>Hyperforin (0.5 μmol/L)</td>
<td>2.52</td>
<td>6.00</td>
</tr>
<tr>
<td></td>
<td>Hyperforin (1.5 μmol/L)</td>
<td>2.63</td>
<td>—</td>
</tr>
<tr>
<td>Ring-hydroxylated</td>
<td>DMSO (0.1%)</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>Rifampin (10 μmol/L)</td>
<td>9.00</td>
<td>18.5</td>
</tr>
<tr>
<td></td>
<td>Hyperforin (0.1 μmol/L)</td>
<td>1.54</td>
<td>1.83</td>
</tr>
<tr>
<td></td>
<td>Hyperforin (0.5 μmol/L)</td>
<td>3.31</td>
<td>4.5</td>
</tr>
<tr>
<td></td>
<td>Hyperforin (1.5 μmol/L)</td>
<td>3.08</td>
<td>—</td>
</tr>
</tbody>
</table>

*Student’s 1-sample, 1-sided t test compared with DMSO control.
† Values represent fold increase in concentration of metabolite compared with the concentration in control hepatocyte cultures treated with DMSO.
lower limit of quantitation (38) of 1 nmol/L and was linear over the range of 1 to 1,000 nmol/L. Based on three triplicate, back-calibrated standard curves, the accuracy of the assay ranged between 93% and 106%. Based on 3-day assays of quality control samples containing 5, 50, or 500 nmol/L docetaxel (six at each concentration), the interday precision of the assay was 2% to 6% at any given concentration and the intraday precision of the assay was 2% to 10%. No materials in incubation medium from hepatocyte cultures interfered with the quantitation of docetaxel or internal standard. Because authentic standards of docetaxel metabolites were not available, absolute quantitation of docetaxel metabolites was not possible and, therefore, relative amounts of these materials present in incubation medium were expressed as the ratio of the area under the proposed metabolite peak to the area under the respective internal standard in that incubation medium. Under the LC/MS/MS conditions described for cytochrome P450 incubations, docetaxel eluted at ~28 minutes.

**Statistics.** Because metabolism in DMSO cultures was assigned a value of 1 and induction was expressed as fold induction over control, Student’s one-sample, one-sided t test was used to test the null hypothesis that induction of docetaxel metabolism yielded a mean value >1. Spearman’s correlation was used to assess the strength of dose dependency of induction of metabolism by hyperforin. All statistical analyses were done with SPSS software, version 12 (SPSS, Inc., Chicago, IL).

**Results**

As indicated in Table 2, rifampin induced metabolism of docetaxel between 6.8- and 32-fold over the metabolism of docetaxel observed in control hepatocyte cultures pretreated with DMSO alone. Hyperforin also induced metabolism of docetaxel and did so in a dose-dependent manner (Table 2). Of note, two sites of docetaxel metabolism were characterized by the LC/MS/MS assay used. Under the LC conditions used for analyzing hepatocyte incubations, the first of these metabolites eluted at ~4.8 minutes (Fig. 1C) and was the previously described tert-butyl–hydroxylated metabolite resulting from CYP3A4 metabolism of docetaxel (Fig. 2B; refs. 33, 39–42). This structural assignment was based upon the mass spectrum fragmentation pattern shown in Fig. 3B. Specifically, two products ions, with m/z 549 and 320, respectively, were observed (Figs. 2B and 3B). The product ion with m/z 549 represented the sodium adduct of the baccatin ring and was also observed in the MS fragmentation of docetaxel (Figs. 2A and 3A). The product ion with m/z 320 (Fig. 3B) represented the sodium adduct of a molecular fragment 16 atomic mass units greater than the m/z 304 fragment resulting from the sodium adduct of the side chain portion of docetaxel (Figs. 2A and 3A). Induction of this metabolism ranged between 1.3- to 2-fold for 0.1 μmol/L hyperforin to 2.6- to 7-fold for 1.5 μmol/L hyperforin (Spearman ρ, 0.82; P = 0.01; Table 2). Of note, an apparent metabolite of docetaxel, characterized by hydroxylation of the baccatin ring, was also observed in the hepatocyte incubations (Figs. 1D, 2C, and 3C). Under the LC conditions used for analyzing hepatocyte incubations, this proposed metabolite eluted at ~7.7 minutes (Fig. 1D). Structural assignment of ring hydroxylation was based on the mass spectrum fragmentation pattern shown in Fig. 3C. Specifically, two product ions, with m/z 565.5 and 304, respectively, were observed (Figs. 2C and 3C). The product ion with m/z 565.5 represented the sodium adduct of a fragment 16 atomic mass units greater than the m/z 549 ion observed in the MS fragmentation pattern of docetaxel (Figs. 2A and 3A). The product ion with m/z 304 represented the sodium adduct of the molecular fragment known to result from the side chain portion of docetaxel (Figs. 2A and 3A). This proposed baccatin ring hydroxylation of docetaxel was also induced by hyperforin in a dose-dependent manner, with induction ranging from 1.5- to 1.8-fold for 0.1 μmol/L hyperforin to 3- to 5-fold for 1.5 μmol/L hyperforin (Spearman ρ, 0.76, P = 0.03; Table 2).
Fig. 3. LC/MS/MS spectra of the sodium adduct of docetaxel (A); the sodium adduct of the tert-butyl-hydroxylated docetaxel metabolite eluting at 4.8 minutes (B); and the sodium adduct of the proposed baccatin ring-hydroxylated docetaxel metabolite eluting at 7.74 minutes (C).
Incubation of docetaxel with cloned, human CYP3A4 confirmed that isoform as being responsible for production of the tert-butyl-hydroxylated metabolite that eluted at 4.8 minutes under LC conditions initially used to analyze hepatocyte incubations and which eluted at ~8.4 minutes under the LC conditions used to analyze cytochrome P450 incubation mixtures (Fig. 4A and C). Under the LC conditions used to analyze cytochrome P450 incubations, the proposed ring-hydroxylated metabolite that eluted at ~7.7 minutes under the LC conditions initially used to analyze hepatocyte incubations was resolved into two peaks with retention times of ~13.5 and 16.3 minutes, respectively (Fig. 4B). Both of these metabolites were produced by cloned, human CYP3A4 (Fig. 4D), whereas only the metabolite eluting at 16.3 minutes was produced by cloned, human CYP2C8 (Fig. 4E). No metabolites were observed when docetaxel was incubated with CYP2C9.

Discussion

Primary cultures of human hepatocytes offer a number of advantages over other systems commonly used in drug metabolism research. Hepatocytes are intact systems containing all of the necessary cofactors for the oxidative, reductive, and conjugative metabolism of xenobiotics. Yet, their simplicity compared with liver slices, whole perfused organs, or in vivo animal systems allows for the elimination of confounding factors such as blood flow and blood protein binding.

In this study, we have shown that human hepatocytes exposed chronically to the St. John’s wort constituent hyperforin (up to 1.5 μmol/L) had increased cytochrome P450 activity as evidenced by induction of docetaxel metabolism. The limit of 1.5 μmol/L hyperforin was due to the fact that chronic (48 hours) exposure of human hepatocytes to hyperforin concentrations >1.5 μmol/L has been shown to be cytotoxic (13). However, the induction observed with 0.1 and 0.5 μmol/L hyperforin is more likely to reflect the potential clinical situation because peak hyperforin concentrations in plasma of patients taking the commonly used St. John’s wort extract dose of 300 mg tid are ~0.28 μmol/L and steady-state concentrations are ~0.18 μmol/L (43). Although docetaxel metabolism was increased in each of the three hepatocyte preparations, there was some variability in the degree of induction at each of the hyperforin concentrations used. This might reflect a number of factors including age, sex, and medications of the donor. In our studies, each hepatocyte donor was female (44). Our data are unlikely to reflect drugs used by the hepatocyte donors or during hepatocyte preparation because studies were carried out on day 5 or 6 of culture, and our experience is that the effects of drugs used by donors do not last this long. Our use of 100 μmol/L docetaxel reflected several considerations. Whereas 100 μmol/L docetaxel is well above the concentrations achieved in plasma of patients receiving docetaxel, it is within the range of concentrations achieved in the livers of mice treated with i.v. docetaxel in antitumor efficacy studies (45). Furthermore, whereas 100 μmol/L is above the estimated 1 to 10 μmol/L K_m of CYP3A for docetaxel, our studies were done in a setting of presumed induction with increased enzyme content and activity. Therefore, we chose to use 100 μmol/L docetaxel to guarantee the saturating docetaxel concentrations required to perform suitable assessments of enzyme induction. Overall, our data are consistent with reports that St. John’s wort administration induces metabolism and MDR1 P-glycoprotein transport of other CYP3A substrates, such as cyclosporine, indinavir, irinotecan, and imatinib, resulting in decreased plasma or blood concentrations of these drugs (refs. 8–11, 46, 47).

Fig. 4. LC/MS/MS chromatograms of total ion current of product ions monitored for the tert-butyl–hydroxylated metabolite produced by incubating docetaxel with human hepatocytes (A); the baccatin ring-hydroxylated metabolites produced by incubating docetaxel with human hepatocytes (B); the tert-butyl–hydroxylated metabolite produced by incubating docetaxel with cloned, human CYP3A4 (C); the baccatin ring-hydroxylated metabolites produced by incubating docetaxel with cloned, human CYP3A4 (D); and the baccatin ring-hydroxylated metabolite produced by incubating docetaxel with cloned, human CYP2C8 (E).
It should be noted that whereas ring-hydroxylated metabolites of docetaxel and CYP2C8 metabolism of docetaxel have not been reported previously, these observations might reflect the high concentrations of docetaxel used in our studies. Whereas our data indicate hydroxylation of the baccatin ring of docetaxel is catalyzed by both CYP3A4 and CYP2C8, the exact positions hydroxylated remain to be elucidated. It is possible that one of the ring-hydroxylated metabolites is analogous to the 6-α-hydroxy metabolite of paclitaxel produced by CYP2C8.

Although the data presented here clearly document the ability of hyperforin to induce the in vitro metabolism of docetaxel by human hepatocytes, in vivo preclinical and, eventually, clinical studies will be required to document the overall impact of hyperforin on docetaxel clearance. However, ethical concerns may make design of a clinical study involving exposure of patients to the intended combination of hyperforin and docetaxel difficult. If an inactivating outcome is expected, the only way in which such clinical studies could be done would be in a cohort of patients already taking St. John’s wort.

However, using each patient as his or her own control would require studying the pharmacokinetics of docetaxel in that patient when that patient would not be taking St. John’s wort. If the clearance of St. John’s wort would be decreased while the patient were off St. John’s wort and the patient experienced an increased area under the curve, the patient might well experience increased neutropenia or other toxicity, again raising serious ethical issues about the ability to do such a trial.

Nevertheless, in that many antineoplastic agents are substrates for CYP3A4 and other cytochrome P450s induced by St. John’s wort, the chronic use of St. John’s wort by patients with cancer could result in subtherapeutic exposure to those antineoplastic agents.

Acknowledgments

We thank Jeremy A. Hedges for excellent secretarial assistance; Rosemarie Mick, M.S., for statistical assistance and education; Steven M. Musser, Ph.D., for assistance with interpretation of mass spectra; and Jerry M. Collins, Ph.D., and the University of Pittsburgh Cancer Institute Hematology/Oncology Writing Group for constructive criticism related to this article.

References


Cancer Therapy: Preclinical


Effect of the St. John's Wort Constituent Hyperforin on Docetaxel Metabolism by Human Hepatocyte Cultures


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/19/6972

Cited articles
This article cites 42 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/19/6972.full.html#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/11/19/6972.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.